Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:38 2024-12-04 am EST			5-day change	1st Jan Change
90.10 ^CHF	-3.14%		-2.86%	+6.16%

Dec. 04	Novartis cannot block generic of best-selling heart drug, US appeals court says	RE
Dec. 04	HSBC Downgrades Novartis to Reduce, Price Target is $95	MT

NOVARTIS AG : JP Morgan remains Neutral

August 31, 2023 at 02:21 am EDT

JP Morgan's research confirms his advice and maintains his neutral opinion on the stock. The target price is unchanged and still at CHF 95.

Latest news about Novartis AG

Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call	Dec. 02
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement	Dec. 02	MT
PTC Therapeutics Shares Jump on Pact With Novartis	Dec. 02	DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket	Dec. 02	MT
Swiss Market Index Recovers; Nestlé Shares Edge Up	Nov. 27	MT
Global markets live: HP, Dell, Amazon, EasyJet, HSBC...	Nov. 27
Novartis Receives European Commission Approval for Adjuvant Early Breast Cancer Treatment	Nov. 27	MT
Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment	Nov. 27	MT
Novartis: has received authorization from the European Commission	Nov. 27	CF
Novartis' Early Breast Cancer Drug Gets Approval from EU Commission	Nov. 27	MT
EU Commission Approves Novartis' Kisqali in Broad Population of Breast Cancer Patients	Nov. 27	MT
Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence	Nov. 27	DJ
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence	Nov. 27	CI
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation	Nov. 26	MT
Novartis: to present data at annual meeting	Nov. 25	CF
NOVARTIS : Stifel raises its target price for the share	Nov. 25	CF

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2024-12-07 - American Society of Hematology Meeting - Abstract Number - 67

More about the company